CGF166: Phase I/II restarted

According the GenVec, Novartis notified the biotech that a DSMB recommended continuation of an open-label, U.S. Phase I/II trial of CGF166 based on the DSMB’s review of safety and efficacy data from the 9 enrolled patients. GenVec believes Novartis will restart enrollment “in the coming months” and complete the trial next year. In January, GenVec said the pharma paused enrollment in the study to conduct a safety review based on the DSMB’s recommendation (see BioCentury, Feb. 1) ...